← All thesesMRNAUnattractiveHigh convictionTuesday 17 November 2026עברית

Moderna

This is the archived full research. Read the story

The maker of one of the two mRNA COVID vaccines, now betting its future on a cancer vaccine built from each patient's own tumour.

Our viewUnattractive High conviction
The scores
The profile · 1-4
Growth1/4 ↑

Revenue fell from $19.3B in 2022 to $1.9B in 2025; Q3 2026 grew 29% and 2026 is guided up 15% to 25%.

Business quality2/4 ↑

The vaccines have no moat: sales fell 90%. Intismeran's Phase 3 is a real lead, but unproven in sales and half Merck's.

Financial position3/4 →

About $8.0B of cash and investments against $3.5B of debt due from 2031; liquidity above $9B covers a yearly gap near $1.5B.

Execution record2/4 ↑

Built the COVID vaccine at record speed, then missed revenue guides as demand fell; since then it cut costs and delivered the melanoma trial.

Per share capture2/4 →

Half of intismeran's profit goes to Merck, stock pay runs near a fifth of sales, and convertibles add about 14M shares.

Potential3/4 ↑

A positive Phase 3 in melanoma, three more Phase 3 trials enrolled in common cancers, and a 2027 launch planned; none has yet sold.

Risk profile2/4 →

Value rests on one medicine whose survival benefit is unproven, a rival's version failed in another cancer, and patent suits run both ways.

Valuation1/4 →

The price is about 552% of a value near $39 and above the bull case near $78 (C44), pricing success across several cancers (C45).

Evidence quality3/4 →

Filed statements, the trial result as presented to doctors, government cancer and vaccination data; the analyst day and the veterans study are secondhand.

The bet · 2-3 years
Priced for success0.2×

If it works 0.2× · if it fails you keep about 12%.

The Verdict

We rate Moderna Unattractive. Its COVID vaccines, nearly all of its sales, keep shrinking and lose money, so the business is weak today. Its cancer vaccine, made with Merck, cut melanoma coming back by 42% in a large trial, a real result. But Merck keeps half of any profit, other cancers are untested, and a rival's version failed in bowel cancer. The price is about 552% of our value of about $39 a share and above even our optimistic case: it is stretched, paying for success across many cancers. As a bet it is priced: even a big win adds little.

The long caseIf a vaccine made from each patient's tumour keeps cancer from returning after surgery, it could be added to standard treatment in several common cancers.

How we weighed it

The price against our value

Against it

Price at 552% of our value

The price sits far above our value and above the bull case.

The business

Against it

Weak

The vaccines have no moat and the cancer vaccine has not yet sold.

Growth against what the price assumes

Cuts both ways

Sales grow again this year, but off a base a tenth of the peak, and the price assumes far more.

What could go wrong

Against it

Survival is unproven, a rival's version failed in another cancer, and Merck keeps half.

Against competitors

Against it

Priced at many times its filed rivals on sales.

How its group is behaving

Cuts both ways

It sits in none of our ranked groups; trial news moves it, not the market.

The latest news and report

In its favour

A positive late-stage trial, a strong quarter and a filing planned by year-end.

The evidence under this - 6 claims
C44inferencemedium confidence
Valued in three stages at an 8% required return on the analysts' revenue path, with stock pay a cost fading to 6% of sales, Moderna is worth about $39 a share (bear $16.70, bull $78.13), so $215.27 is about 552% of the base case.
against this

The analysts' path may undercount intismeran in lung and other cancers; the bull case is the check, and the price is still nearly three times it.

current state · 2026-11-16written 2026-11-17
C45inferencemedium confidence
At $215.27 the market prices Moderna at 33 times trailing sales and about 10 times the analysts' 2030 revenue of $8.22B: the price assumes intismeran succeeds across several cancers and the vaccine business stabilises.
against this

A rival with a proven cancer platform could be worth this; the price could be pricing a platform beyond intismeran.

current state · 2026-11-16written 2026-11-17
C10facthigh confidence
In the Phase 3 INTerpath-001 trial, 1,137 patients with high-risk melanoma removed by surgery got intismeran with Keytruda or Keytruda alone; after a median follow-up of 24.6 months recurrence or death fell 42% (hazard ratio 0.58, 95% CI 0.45 to 0.75), 82.2% against 70.0% were free of recurrence at two years, and survival data are immature.
against this

Overall survival is not yet shown, and the trial compares against Keytruda alone, not against other add-on treatments.

historical · INTerpath-001 interim analysis, 2026written 2026-11-17
C11facthigh confidence
Moderna and Merck develop intismeran together: Merck paid $250M to exercise its option in 2022, the two share costs and any profits or losses equally worldwide, Merck leads the trials and Moderna makes the vaccine.
current state · 2025-12-31written 2026-11-17
C02facthigh confidence
2025 revenue was $1,944M, of which COVID-19 vaccines were $1,810M (93.1%) and mRESVIA $8M; the rest was grants and collaboration revenue.
historical · 2025written 2026-11-17
C14facthigh confidence
BioNTech terminated its Phase 2 colorectal cancer trial of autogene cevumeran, the closest rival individualized mRNA cancer vaccine, in August 2026 after its safety board found a numerical imbalance in overall survival.
historical · 2026written 2026-11-17
01

The company

Moderna's vaccines carry a set of genetic instructions that tell the body's own cells to make a harmless piece of a virus, so the immune system learns to recognise it. It sells shots against COVID, RSV and, since August 2026, flu to governments, pharmacies and health systems.

Its cancer vaccine works the same way, but it is made for one patient at a time from the mutations in that patient's removed tumour, and given with Merck's Keytruda to stop the cancer returning.

The evidence under this - 3 claims
C01facthigh confidence
Moderna sells mRNA vaccines: Spikevax and mNEXSPIKE against COVID-19, mRESVIA against RSV and, since its US approval in August 2026, mFLUSIVA against flu; a flu and COVID combination is approved in the EU and Canada, five approved vaccines in all.
current state · 2026-11-06written 2026-11-17
C10facthigh confidence
In the Phase 3 INTerpath-001 trial, 1,137 patients with high-risk melanoma removed by surgery got intismeran with Keytruda or Keytruda alone; after a median follow-up of 24.6 months recurrence or death fell 42% (hazard ratio 0.58, 95% CI 0.45 to 0.75), 82.2% against 70.0% were free of recurrence at two years, and survival data are immature.
against this

Overall survival is not yet shown, and the trial compares against Keytruda alone, not against other add-on treatments.

historical · INTerpath-001 interim analysis, 2026written 2026-11-17
C12management claimmedium confidence
At its 12 November 2026 analyst day Moderna said it will seek US approval of intismeran by year-end and aims for a 2027 launch, with Merck sharing the US launch and leading outside it, about $4B of company spending in 2027 and more than $9B of liquidity at the end of 2026.
against this

A filing is not an approval, and an individualized medicine made for each patient has no precedent at this scale.

forwardwritten 2026-11-17

How it makes money

Today almost every dollar comes from seasonal vaccines sold each autumn, mostly COVID shots, so sales swing by quarter: $1.31B in the third quarter of 2026, but $2.53B over twelve months against a loss of $2.93B. If the cancer vaccine is approved, Moderna makes it and Merck shares the selling, and the two split the costs and any profit equally.

The evidence under this - 4 claims
C02facthigh confidence
2025 revenue was $1,944M, of which COVID-19 vaccines were $1,810M (93.1%) and mRESVIA $8M; the rest was grants and collaboration revenue.
historical · 2025written 2026-11-17
C04facthigh confidence
Q3 2026 revenue was $1,313M, up 29%: COVID-19 vaccines $1,244M and mRESVIA $29M; US sales $771M, Europe $314M against $16M a year earlier, the rest of the world $188M. Net income was $162M, $0.38 a diluted share.
against this

One quarter: the COVID season is concentrated in the third and fourth quarters, and the nine-month result is still a large loss.

historical · Q3 2026written 2026-11-17
C05facthigh confidence
In the twelve months to 30 September 2026 revenue was $2,525M, the operating loss $2,930M, stock pay $464M and cash used in operations $1,785M.
historical · twelve months to 2026-09-30written 2026-11-17
C11facthigh confidence
Moderna and Merck develop intismeran together: Merck paid $250M to exercise its option in 2022, the two share costs and any profits or losses equally worldwide, Merck leads the trials and Moderna makes the vaccine.
current state · 2025-12-31written 2026-11-17
Where the money comes from, stream by stream
StreamShare of sales (2025)How it earns it
COVID-19 vaccines (Spikevax, mNEXSPIKE)93%Seasonal shots sold to governments, pharmacies and health systems, mostly in the autumn.
RSV vaccine (mRESVIA)under 1%A vaccine for older adults, launched in 2024 after GSK's and Pfizer's.
Other revenueabout 7%Grants, collaboration revenue and fees for keeping plants ready for governments.

Who runs it

Stéphane Bancel has run Moderna since 2011 and owns 7.6% of the shares; co-founder and chairman Noubar Afeyan owns 1.8%. A new chief operating officer, Juan Andres, returned in October 2026 to run manufacturing for the launch.

Bancel's bonus paid 170% of target in 2025, while his share awards tied to results vested at about half. Insiders bought no shares in the past year and sold 1,073,172, nearly all under plans set in advance.

The evidence under this - 3 claims
C27facthigh confidence
Stéphane Bancel owns 30,652,258 shares, 7.6%; Noubar Afeyan 1.8%; officers and directors 10.8%; FMR 10.4%, Vanguard 9.8%, BlackRock 6.4% and Baillie Gifford 5.2%.
current state · 2026-03-16written 2026-11-17
C28facthigh confidence
Bancel's 2025 pay was a $1,687,200 salary, a $4,302,360 bonus at 170% of target and $15M of equity, half options and half performance units; the 2022 and 2023 performance units vested at 55% and 50% of target.
historical · 2025written 2026-11-17
C29facthigh confidence
In the year to November 2026 insiders made 22 open-market sales of 1,073,172 shares, 96.9% of them under Rule 10b5-1 plans, and no purchases; Bancel sold about 499,000 shares on 5 August 2026 at $56 to $59 under a plan dated 4 May.
current state · 2026-11-09written 2026-11-17
02

Why it wins, and who could beat it

Why customers come back

In vaccines there is little to keep a buyer: governments and pharmacies switch on price and data each season.

The cancer vaccine is different. It is the only personalised vaccine with a positive late-stage trial, and BioNTech's version stopped its bowel cancer trial. A US biologic gets 12 years of protection from copies, and a rival needs its own large trial in each cancer. That lead is real, but it has not yet earned a dollar.

The evidence under this - 3 claims
C10facthigh confidence
In the Phase 3 INTerpath-001 trial, 1,137 patients with high-risk melanoma removed by surgery got intismeran with Keytruda or Keytruda alone; after a median follow-up of 24.6 months recurrence or death fell 42% (hazard ratio 0.58, 95% CI 0.45 to 0.75), 82.2% against 70.0% were free of recurrence at two years, and survival data are immature.
against this

Overall survival is not yet shown, and the trial compares against Keytruda alone, not against other add-on treatments.

historical · INTerpath-001 interim analysis, 2026written 2026-11-17
C14facthigh confidence
BioNTech terminated its Phase 2 colorectal cancer trial of autogene cevumeran, the closest rival individualized mRNA cancer vaccine, in August 2026 after its safety board found a numerical imbalance in overall survival.
historical · 2026written 2026-11-17
C38facthigh confidence
A US biologic gets 12 years of data exclusivity from first licensure before a copy can be approved.
current state · 2025-12-31written 2026-11-17

The threat

Pfizer and BioNTech sell the larger COVID vaccine, and Comirnaty's sales are shrinking too. Novavax sells a protein-based shot through Sanofi, and GSK and Pfizer reached the RSV market first. In cancer the closest rival is BioNTech's own personalised vaccine, which failed in bowel cancer.

The evidence under this - 4 claims
C37facthigh confidence
Moderna's 10-K names Pfizer and BioNTech as its main COVID-19 vaccine rivals, Sanofi and Novavax as others, and Pfizer and GSK, which entered the US market first, in RSV.
current state · 2025-12-31written 2026-11-17
C18facthigh confidence
Pfizer's Comirnaty sold $808M in the quarter to 27 September 2026 against $1,151M a year earlier, and $1,301M in nine months against $2,097M; its RSV vaccine Abrysvo sold $303M in the quarter against $279M.
historical · Q3 2026written 2026-11-17
C20facthigh confidence
Novavax's protein-based COVID-19 vaccine, Nuvaxovid, is now sold through Sanofi.
current state · 2025-12-31written 2026-11-17
C14facthigh confidence
BioNTech terminated its Phase 2 colorectal cancer trial of autogene cevumeran, the closest rival individualized mRNA cancer vaccine, in August 2026 after its safety board found a numerical imbalance in overall survival.
historical · 2026written 2026-11-17

The rivals: PFE, BNTX, NVAX, SNY, GSK, MRK.

Who else does this, rival by rival
TickerRivalWhere it competesHow far alongPriced against it
PFE · BNTXPfizer and BioNTech's ComirnatyPriced against it: YesRespiratory vaccines: COVID, RSV and fluOn saleYes
NVAX · SNYNovavax's Nuvaxovid, sold by Sanofi, and Sanofi's flu vaccinesPriced against it: YesRespiratory vaccines: COVID, RSV and fluOn saleYes
GSK · PFEGSK's Arexvy and Pfizer's Abrysvo against RSVPriced against it: One segment onlyRespiratory vaccines: COVID, RSV and fluOn saleOne segment only
BNTXBioNTech's autogene cevumeran, its own individualized mRNA cancer vaccinePriced against it: YesCancer and rare-disease medicines in developmentIn researchYes
MRKMerck's Keytruda alone after surgeryPriced against it: Not checkedCancer and rare-disease medicines in developmentOn saleNot checked
03

How big it could get

How big this could get

About 112,000 Americans will be found with melanoma in 2026, and roughly 11,000 of them with cancer that has reached nearby lymph nodes, the kind the trial treated. A year of Keytruda lists at about $217,000, so melanoma alone could be about $2.4B a year in the US at full use, before Merck takes its half. Lung cancer, if its trial works, would be far larger.

The evidence under this - 4 claims
C15facthigh confidence
The US National Cancer Institute expects 112,000 new cases of melanoma of the skin and 8,510 deaths in 2026; 76.9% are found at the local stage and about 10% at the regional stage.
current state · 2026-04-01written 2026-11-17
C42inferencelow confidence
About 11,000 Americans a year are found with melanoma that has reached nearby lymph nodes, the group the trial treated after surgery; at a year of Keytruda's price that is roughly $2.4B a year in the US at full use.
against this

The trial's eligible group is not exactly the regional stage, and Moderna keeps only half of any profit (C11).

current state · 2026-11-17written 2026-11-17
C41inferencemedium confidence
A year of Keytruda at list price, about 17 doses every three weeks, costs about $217,000.
against this

List price is not what payers pay after discounts, and intismeran's own price is not set.

current state · 2026-09-01written 2026-11-17
C11facthigh confidence
Moderna and Merck develop intismeran together: Merck paid $250M to exercise its option in 2022, the two share costs and any profits or losses equally worldwide, Merck leads the trials and Moderna makes the vaccine.
current state · 2025-12-31written 2026-11-17

Who has signed

Merck has signed to share the cancer vaccine's costs and profits equally worldwide. Canada, the United Kingdom and Australia have long-term vaccine partnerships with plants built on their soil, and Recordati licensed a rare-disease medicine for $50M upfront.

The evidence under this - 3 claims
C11facthigh confidence
Moderna and Merck develop intismeran together: Merck paid $250M to exercise its option in 2022, the two share costs and any profits or losses equally worldwide, Merck leads the trials and Moderna makes the vaccine.
current state · 2025-12-31written 2026-11-17
C39facthigh confidence
Moderna has government partnerships with plants in Canada, the United Kingdom and Australia; Canada's Laval plant delivered its first fully made vaccines in September 2025.
current state · 2025-12-31written 2026-11-17
C31facthigh confidence
Moderna licensed its propionic acidemia medicine to Recordati in 2026 for $50M upfront plus milestones and royalties, keeping the trials through approval.
current state · 2026-09-30written 2026-11-17
04

The results

The numbers

Is it growing?Steady

Sales grew 13% over the twelve months to Sep 2026, faster than the −40% in the year to Dec 2025.

Dec 2021: $18.5BDec 2022: $19.3BDec 2023: $6.85BDec 2024: $3.24BDec 2025: $1.94B12 mo to Sep 2026: $2.52B$18.5B$2.52B
Is it profitable?Losing

Operating margin is −116%, down from −62% in the year to Dec 2023.

Dec 2021: 72%Dec 2022: 49%Dec 2023: −62%Dec 2024: −122%Dec 2025: −158%12 mo to Sep 2026: −116%72%−116%
Does growth pay off?Unclear

Running costs take 144¢ of each sales dollar, up from 14¢ in the year to Dec 2021.

Dec 2021: 14¢Dec 2022: 23¢Dec 2023: 93¢Dec 2024: 177¢Dec 2025: 213¢12 mo to Sep 2026: 144¢14¢144¢
Does it earn good returns?Poor

Shareholders' money lost 35% a year, down from 146% in the year to Dec 2021.

Dec 2021: 146%Dec 2022: 50%Dec 2023: −29%Dec 2024: −29%Dec 2025: −29%12 mo to Sep 2026: −35%146%−35%
How long can it keep going?Limited

It used $1.97B of cash over the last twelve months, so the $5.17B it holds lasts about 2.6 years at that pace.

Dec 2021: $13.3BDec 2022: $4.58BDec 2023: −$3.83BDec 2024: −$4.05BDec 2025: −$2.06B12 mo to Sep 2026: −$1.97B$13.3B−$1.97B
Is the balance sheet safe?Net cash

It holds $5.17B of cash against $3.55B of debt, $1.62B more cash than it owes.

Dec 2024: $7.03BDec 2025: $5.21B12 mo to Sep 2026: $1.62B$7.03B$1.62B
Are shares being diluted?Stable

The share count barely moved in 4.8 years, and pay in shares costs 18% of sales.

Dec 2021: 431MDec 2022: 416MDec 2023: 382MDec 2024: 384MDec 2025: 389M12 mo to Sep 2026: 430M431M430M
All the numbers

Filed figures from the company's 10-K and 10-Q, read 2026-11-17. Fiscal years end in December.

Dec 2021Dec 2022Dec 2023Dec 2024Dec 202512 mo to Sep 2026
Size and growth
Sales$18.5B$19.3B$6.85B$3.24B$1.94B$2.52B
Sales growth+22×+4.3%−64%−53%−40%+13%
Profit
Gross margin86%72%31%55%55%28%
Operating margin72%49%−62%−122%−158%−116%
Net margin66%43%−69%−110%−145%−110%
What growth costs, per sales dollar
Research and development11%17%71%140%161%105%
General and admin3.1%5.9%23%36%52%-
Pay in shares0.8%1.2%4.5%13%25%18%
Capital spending1.5%2.1%10%32%9.9%7.3%
Cash
Cash from operations$13.6B$4.98B−$3.12B−$3.00B−$1.87B−$1.78B
Free cash flow$13.3B$4.58B−$3.83B−$4.05B−$2.06B−$1.97B
Balance sheet
Cash and short-term investments$10.7B$9.90B$8.60B$7.03B$5.80B$5.17B
Debt---$0$590M$3.55B
Net cash---$7.03B$5.21B$1.62B
Returns and shares
Return on capital146%49%----
Shares (diluted)431M416M382M384M389M430M

What growth costs

There has been no growth to pay for: sales fell nine-tenths in three years. Moderna cut research from $4.5B in 2024 to $3.1B in 2025 and building spending almost to nothing, and plans about $2.7B of research this year. The loss is shrinking because costs fall, not because sales rise.

The evidence under this - 3 claims
C03facthigh confidence
Revenue was $18,471M in 2021, $19,263M in 2022, $6,848M in 2023, $3,236M in 2024 and $1,944M in 2025; operating income went from $13,296M and $9,420M to losses of $4,239M, $3,945M and $3,074M.
historical · 2021-2025written 2026-11-17
C33facthigh confidence
Research spending fell from $4,543M in 2024 to $3,132M in 2025, capital spending from $1,051M to $192M; stock pay was $429M and $483M, and cash used in operations $1,873M in 2025.
historical · 2024-2025written 2026-11-17
C06management claimmedium confidence
For 2026 Moderna guides revenue up 15% to 25%, cost of sales about $1.7B including the $0.9B patent settlement, research about $2.7B, selling and admin about $1.0B, capital spending about $0.2B and year-end cash of $8.1B to $8.3B.
against this

Revenue guidance has been cut repeatedly since 2023; this one was raised only after a strong third quarter.

forwardwritten 2026-11-17

The last report (6 Nov)

Quarter ended September 2026, filed figures.

29%
Sales growth
against the same quarter a year earlier
10¢
Operating profit
per dollar of sales

In the quarter to September 2026 sales rose 29% to $1.31B and Moderna earned $162M, helped by European sales of $314M against $16M a year earlier. Research spending fell 27%.

Management now expects 2026 sales to grow 15% to 25%, up from up to 10% in January, and year-end cash of $8.1B to $8.3B. Nine months still used $2.72B of cash, including the $950M patent settlement.

What it did to the thesisIt helped the vaccine business: sales grew again and costs kept falling. It left the case where it was, because the price rests on the cancer vaccine, which the quarter did not test, and the business still loses money over the year.

The quarter in detail

Sales growth from the previous quarter, filed figures. The company has restated its own history, so a quarter either side of the restatement may describe a different business; n/c marks one that does not compare.

Earnings per share $0.38 against $-1.10 expected; $0.38 as filed, with no adjustments.

The evidence under this - 4 claims
C04facthigh confidence
Q3 2026 revenue was $1,313M, up 29%: COVID-19 vaccines $1,244M and mRESVIA $29M; US sales $771M, Europe $314M against $16M a year earlier, the rest of the world $188M. Net income was $162M, $0.38 a diluted share.
against this

One quarter: the COVID season is concentrated in the third and fourth quarters, and the nine-month result is still a large loss.

historical · Q3 2026written 2026-11-17
C06management claimmedium confidence
For 2026 Moderna guides revenue up 15% to 25%, cost of sales about $1.7B including the $0.9B patent settlement, research about $2.7B, selling and admin about $1.0B, capital spending about $0.2B and year-end cash of $8.1B to $8.3B.
against this

Revenue guidance has been cut repeatedly since 2023; this one was raised only after a strong third quarter.

forwardwritten 2026-11-17
C36facthigh confidence
Q3 2026 research spending was $583M, down 27%; selling and admin $282M; cost of sales $318M; nine months of operations used $2,715M of cash, including the $950M settlement.
historical · Q3 2026written 2026-11-17
C46facthigh confidence
In January 2026 Moderna said it had cut yearly operating expenses by about $2B in 2025 and guided 2026 revenue growth of up to 10%; by November it guided 15% to 25%.
historical · 2026written 2026-11-17
What management did with the money

Insiders in 2026Q3: 25 purchases and 42 sales, from their Form 4 filings.

05

The price, and where we disagree

In short. Priced for perfection. The price pays for the cancer vaccine succeeding in several common cancers, and is above even our optimistic value.

Share price
$215.27
close,
Company value for each $1 of sales
33.0
rivals' middle 3.1

The shares nearly tripled on 19 August, the day the melanoma trial succeeded, fell about a sixth on 22 October when the full data leaked early, and slipped after the 12 November analyst day.

Moderna plans to ask for US approval by the end of 2026 and to launch with Merck in 2027. The next tests are the fourth-quarter report in February and a kidney cancer trial reading around the turn of the year.

The evidence under this - 4 claims
C40facthigh confidence
On 19 August 2026, the day of the INTerpath-001 topline, the shares closed at $174.38 against $62.96 the day before; on 22 October, when the full data leaked early, they fell from $245.81 to $202.63; after the 12 November analyst day they fell from $248.69 to $215.27 by 16 November.
historical · 2026written 2026-11-17
C12management claimmedium confidence
At its 12 November 2026 analyst day Moderna said it will seek US approval of intismeran by year-end and aims for a 2027 launch, with Merck sharing the US launch and leading outside it, about $4B of company spending in 2027 and more than $9B of liquidity at the end of 2026.
against this

A filing is not an approval, and an individualized medicine made for each patient has no precedent at this scale.

forwardwritten 2026-11-17
C13management claimmedium confidence
Management says the adjuvant lung cancer Phase 3 (INTerpath-002) is fully enrolled, as are the kidney and bladder cancer trials, and the kidney cancer Phase 2 reads out around the turn of 2027.
against this

Enrolment says nothing about results; the closest rival's personalised vaccine failed in another tumour (C14).

current state · 2026-11-06written 2026-11-17
C21facthigh confidence
The shares closed at $215.27 on 16 November 2026, a market value of about $87.1B, up 762% over 252 sessions, against a 52-week range of $22.28 to $280.80.
current state · 2026-11-16written 2026-11-17
The betPriced for success
If it works
0.2×
from today's value, at the stated multiple
If it fails
keep 12%
of today's market value: the rest of the company, less its debt
How we value it
Method
Cash the business will produce, with any shortfall raised in new shares
Required return
8%
Long-run growth
4%
Moat
No moat
BearBaseBull
Sales growth, years 1 to 30.4%, 16.6%, 28%0.8%, 33.2%, 55.9%1%, 41.5%, 69.9%
Normal operating margin16.1%20.2%22.2%
Return on new capital after year ten8%8%11%
Value a share$16.70$38.97$78.13
Price
$215
Priced on
16 Nov
Price as a share of the base value
552%
Yearly return the price offers on the base case
4.9%
Risk check: valued at 12%, the rate for a business not yet making a profit
$22.31

Where each figure comes from

FigureSourceWhere exactly
Sales, the last twelve monthsFiled reportQuarterly report (10-Q) for the period to 30 Sep 2026, filed 6 Nov 2026; the four quarters to that date.
Operating margin todayFiled reportQuarterly report (10-Q) for the period to 30 Sep 2026, filed 6 Nov 2026; the four quarters to that date.
Tax rateOur method's ruleThe normal rate where no rate is filed to read: 25% for a US company, 21% elsewhere.
Sales per dollar of new capitalFiled reportAnnual report (10-K) for the period to 31 Dec 2025, filed 20 Feb 2026: the year's sales over its operating capital.
SharesFiled reportQuarterly report (10-Q) for the period to 30 Sep 2026, filed 6 Nov 2026; the diluted share count.
Cash and investmentsFiled reportQuarterly report (10-Q) for the period to 30 Sep 2026, filed 6 Nov 2026; the balance sheet on that date.
DebtFiled reportQuarterly report (10-Q) for the period to 30 Sep 2026, filed 6 Nov 2026; the balance sheet on that date.
Sales growth, years 1 to 3Analysts' forecastsFMP's consensus for the years to 31 Dec 2026, 31 Dec 2027, 31 Dec 2028 and 31 Dec 2029: the average of 13 to 17 analysts' revenue estimates, 0.8%, 33.2%, 55.9%. FMP publishes how many analysts, not who they are.
Normal operating marginAnalysts' forecastsFMP's consensus operating margin for the year to 31 Dec 2030, the average of 8 analysts' estimates, 26.2%, less stock pay of 6% of sales. FMP publishes how many analysts, not who they are.
Return on new capital after year tenOur method's ruleSet by our reading of the moat: the 8% rate with none, 12% with an average one, 15% with a strong one; the bear case earns the rate.
The bear and bull casesOur method's ruleOur method's spread: the bear case takes half the growth and a fifth off the margin, the bull a quarter more growth and a tenth more margin.
PriceMarket priceFMP's closing price on 16 Nov 2026.
Other investmentsFiled reportQuarterly report (10-Q) for the period to 30 Sep 2026, filed 6 Nov 2026; the balance sheet on that date.

What each case rests on

Bear caseGrowth runs at half the analysts' path, 0.4%, 16.6% and 28.0%, the margin settles a fifth lower at 16.1%, and new capital earns only the 8% rate: intismeran's launch slow and the vaccines still shrinking.

Base caseRevenue grows 0.8%, 33.2% and 55.9% over three years, the analysts' path (C26) that already carries intismeran's launch, then fades toward 4%, closing 30% of the gap each year; the margin moves to 20.2%, the analysts' 2030 figure after stock pay, which is 18.4% of sales today and fades to a mature 6%.

Bull caseGrowth runs a quarter above the analysts' path, 1.0%, 41.5% and 69.9%, as lung cancer and other tumours follow melanoma, the margin reaches 22.2%, and new capital earns 11%.

What moves the base value

LowerHigher
Growth in years 1 to 3, a quarter lower or higher$28.83$53.45
The normal margin, 15% lower or higher$33.00$45.29
Capital per dollar of growth, a quarter more or less$38.16$39.91
Return on new capital after year ten, at the rate or one step up$38.97$51.70
The rate, a point higher or lower$29.22$55.71
Long-run growth a point lower$38.03-

Value a share as growth and margin change

Normal margin ↓ · growth →50%75%100%125%150%
16.2%$16.75$22.79$31.04$42.64$56.80
18.2%$18.86$25.81$34.98$48.02$63.87
20.2%$20.98$28.83$38.97$53.45$70.98
22.2%$23.09$31.87$43.17$58.93$78.12
24.2%$25.22$34.91$47.42$64.46$85.28

Growth is shown as a share of the base case's. Green: the price is at or under 80% of that value. Red: at or over 120%.

How we read the multiple

Moderna has no profit to price, so we value it on the analysts' sales path, which already includes the cancer vaccine's launch, counting stock pay as a cost and requiring an 8% yearly return.

The analysts expect sales of $8.22B in 2030, against about $2.29B this year. Even then the business is worth about $39 a share, and about $78 in our optimistic case, against a price of $215.

Against its own history. Far above anything it has fetched since the pandemic; the gap is the price of a cancer vaccine that has not yet sold.

The evidence under this - 4 claims
C44inferencemedium confidence
Valued in three stages at an 8% required return on the analysts' revenue path, with stock pay a cost fading to 6% of sales, Moderna is worth about $39 a share (bear $16.70, bull $78.13), so $215.27 is about 552% of the base case.
against this

The analysts' path may undercount intismeran in lung and other cancers; the bull case is the check, and the price is still nearly three times it.

current state · 2026-11-16written 2026-11-17
C45inferencemedium confidence
At $215.27 the market prices Moderna at 33 times trailing sales and about 10 times the analysts' 2030 revenue of $8.22B: the price assumes intismeran succeeds across several cancers and the vaccine business stabilises.
against this

A rival with a proven cancer platform could be worth this; the price could be pricing a platform beyond intismeran.

current state · 2026-11-16written 2026-11-17
C26estimatemedium confidence
Analysts expect revenue of $2.29B in 2026 (16 analysts), $2.64B in 2027, $3.69B in 2028, $5.98B in 2029 and $8.22B in 2030, with earnings per share turning positive at $0.84 in 2029 and $4.32 in 2030.
against this

Nine analysts forecast 2029 and fewer 2030; the jump in 2029 rests on intismeran sales nobody has yet seen.

forwardwritten 2026-11-17
C23facthigh confidence
Company value is about $83.3B once cash and investments are netted, 33.0 times trailing sales against 3.9 for BioNTech and 2.4 for Novavax.
against this

Both peers sell mostly COVID vaccines and price little for oncology, so the gap measures the cancer pipeline as much as the vaccine business.

current state · 2026-11-16written 2026-11-17
Priced against its rivals

The competitors its own annual report names, each confirmed against the rival's filing. Measured on company value for each $1 of sales, cheapest first:

TickerCompanycompany value for each $1 of sales
NVAXNovavax2.4×
BNTXBioNTech SE3.9×
MRNAModerna33.0×

The middle of the other 2 is 3.1. Moderna, Inc. is dearest of 3.

Rivals' figures come from a data provider, so read the spread of the group rather than any single pair.

Many times its filed vaccine rivals, which price their shots and little else; the gap is Moderna's own, the cancer vaccine.

The bet: what it pays if it works

This bet is on the cancer vaccine and the rare-disease medicines. It works if the vaccine is approved, launched with Merck and then spreads beyond melanoma.

Even a large win in melanoma, with Moderna's half of the profit, would be worth only a fraction of today's company value. If it fails, shareholders keep a shrinking vaccine business worth a small part of the price, so the bet is priced and expensive.

Cancer and rare-disease medicines in development revenue in two to three yearsPatient-years at a year of Keytruda's list price neededAt the stated multiple
$300.00Mabout 2.8K at 50% kept0.1×
$1.00B (the big win)about 9.2K at 50% kept0.2×
$2.50Babout 23.0K at 50% kept0.3×

To pay 2× (a Fair bet) it would need about $20.03B of Cancer and rare-disease medicines in development revenue (about 184.6K patient-years at a year of Keytruda's list price at 50% kept); to pay 5× (a Cheap bet), about $51.27B of Cancer and rare-disease medicines in development revenue (about 472.6K patient-years at a year of Keytruda's list price at 50% kept), at the same multiple.

Each row is Cancer and rare-disease medicines in development alone, plus the rest of the company (Respiratory vaccines: COVID, RSV and flu) counted at about $6.34B.

The steps it has to take

  • Done Phase 3 in melanoma meets its main goal
  • In progress US approval filing for intismeran in melanoma due 2026-12
  • In progress Kidney cancer Phase 2 reads out due 2027-03
  • Not started US approval and launch in melanoma with Merck due 2027-12
  • In progress Lung cancer Phase 3 reports its first analysis due 2028-12
The detail behind the label
Rating
Expensive
the big win's payoff against the 2× and 5× lines
Cheap bet at about
≈ $16.47
92% below the price (close, )
The option
0.1×
what Cancer and rare-disease medicines in development is worth if it works, against what the price pays for it
The evidence under this - 6 claims
C10facthigh confidence
In the Phase 3 INTerpath-001 trial, 1,137 patients with high-risk melanoma removed by surgery got intismeran with Keytruda or Keytruda alone; after a median follow-up of 24.6 months recurrence or death fell 42% (hazard ratio 0.58, 95% CI 0.45 to 0.75), 82.2% against 70.0% were free of recurrence at two years, and survival data are immature.
against this

Overall survival is not yet shown, and the trial compares against Keytruda alone, not against other add-on treatments.

historical · INTerpath-001 interim analysis, 2026written 2026-11-17
C12management claimmedium confidence
At its 12 November 2026 analyst day Moderna said it will seek US approval of intismeran by year-end and aims for a 2027 launch, with Merck sharing the US launch and leading outside it, about $4B of company spending in 2027 and more than $9B of liquidity at the end of 2026.
against this

A filing is not an approval, and an individualized medicine made for each patient has no precedent at this scale.

forwardwritten 2026-11-17
C11facthigh confidence
Moderna and Merck develop intismeran together: Merck paid $250M to exercise its option in 2022, the two share costs and any profits or losses equally worldwide, Merck leads the trials and Moderna makes the vaccine.
current state · 2025-12-31written 2026-11-17
C41inferencemedium confidence
A year of Keytruda at list price, about 17 doses every three weeks, costs about $217,000.
against this

List price is not what payers pay after discounts, and intismeran's own price is not set.

current state · 2026-09-01written 2026-11-17
C23facthigh confidence
Company value is about $83.3B once cash and investments are netted, 33.0 times trailing sales against 3.9 for BioNTech and 2.4 for Novavax.
against this

Both peers sell mostly COVID vaccines and price little for oncology, so the gap measures the cancer pipeline as much as the vaccine business.

current state · 2026-11-16written 2026-11-17
C14facthigh confidence
BioNTech terminated its Phase 2 colorectal cancer trial of autogene cevumeran, the closest rival individualized mRNA cancer vaccine, in August 2026 after its safety board found a numerical imbalance in overall survival.
historical · 2026written 2026-11-17

Where we disagree with the market

The market believes

The cancer vaccine works, so Moderna is now a cancer company with a technology worth paying up for.

We believe

The melanoma result is real, but Merck takes half the profit and the vaccines keep shrinking, so even our optimistic value sits far below the price.

The market has priced the technology as proven in many cancers. It has worked in one, the survival benefit is not yet shown, and a rival's version failed in another.

The evidence against us: if the lung cancer trial succeeds and the launch is priced near a year of Keytruda, the vaccine could be far bigger than the analysts expect.

What analysts say, and the evidence
Analysts positive
17%
of 24, 1 Nov
Four months earlier
16%
of 25, 1 Jul
The evidence under this - 6 claims
C10facthigh confidence
In the Phase 3 INTerpath-001 trial, 1,137 patients with high-risk melanoma removed by surgery got intismeran with Keytruda or Keytruda alone; after a median follow-up of 24.6 months recurrence or death fell 42% (hazard ratio 0.58, 95% CI 0.45 to 0.75), 82.2% against 70.0% were free of recurrence at two years, and survival data are immature.
against this

Overall survival is not yet shown, and the trial compares against Keytruda alone, not against other add-on treatments.

historical · INTerpath-001 interim analysis, 2026written 2026-11-17
C11facthigh confidence
Moderna and Merck develop intismeran together: Merck paid $250M to exercise its option in 2022, the two share costs and any profits or losses equally worldwide, Merck leads the trials and Moderna makes the vaccine.
current state · 2025-12-31written 2026-11-17
C14facthigh confidence
BioNTech terminated its Phase 2 colorectal cancer trial of autogene cevumeran, the closest rival individualized mRNA cancer vaccine, in August 2026 after its safety board found a numerical imbalance in overall survival.
historical · 2026written 2026-11-17
C22facthigh confidence
Over the same 252 sessions revenue per share rose 3.1% while the multiple of sales rose about 736%: the rise was the rating, not the business.
current state · 2026-11-16written 2026-11-17
C24facthigh confidence
Analysts rate the shares 7 buy, 16 hold and 6 sell; 16.7% of 24 were positive in November against 16.0% in July, while the average price target of the last month, $251.67 on three targets, is three times the year's $83.77.
current state · 2026-11-16written 2026-11-17
C44inferencemedium confidence
Valued in three stages at an 8% required return on the analysts' revenue path, with stock pay a cost fading to 6% of sales, Moderna is worth about $39 a share (bear $16.70, bull $78.13), so $215.27 is about 552% of the base case.
against this

The analysts' path may undercount intismeran in lung and other cancers; the bull case is the check, and the price is still nearly three times it.

current state · 2026-11-16written 2026-11-17
06

What could go wrong, and how we would know

The risks

  • Survival not yet shown. The trial proved fewer cancers came back; if lives are not lengthened, insurers may refuse to pay on top of Keytruda.
  • One medicine carries the price. A miss in lung cancer, or a rival's failure repeating in another tumour, would remove most of what the shares pay for.
  • Shrinking vaccines. Only about one adult in six took last season's COVID shot, and sales keep falling across the industry.
  • Making a medicine per patient. Each dose is built from one tumour; slow or costly manufacturing could limit how many patients are treated.
  • Patents cut both ways. Moderna paid $950M to settle one suit, lost a European patent this year and still sues Pfizer and BioNTech.
The evidence under this - 6 claims
C10facthigh confidence
In the Phase 3 INTerpath-001 trial, 1,137 patients with high-risk melanoma removed by surgery got intismeran with Keytruda or Keytruda alone; after a median follow-up of 24.6 months recurrence or death fell 42% (hazard ratio 0.58, 95% CI 0.45 to 0.75), 82.2% against 70.0% were free of recurrence at two years, and survival data are immature.
against this

Overall survival is not yet shown, and the trial compares against Keytruda alone, not against other add-on treatments.

historical · INTerpath-001 interim analysis, 2026written 2026-11-17
C14facthigh confidence
BioNTech terminated its Phase 2 colorectal cancer trial of autogene cevumeran, the closest rival individualized mRNA cancer vaccine, in August 2026 after its safety board found a numerical imbalance in overall survival.
historical · 2026written 2026-11-17
C17facthigh confidence
The CDC reports that 17.5% of US adults had taken the 2025-26 COVID-19 vaccine by 22 February 2026.
current state · 2026-02-22written 2026-11-17
C30facthigh confidence
Moderna paid $950M in July 2026 to settle the Arbutus and Genevant patent suits with no future royalties, settled with GSK on 28 October 2026 by cross-licence without payment, lost a European patent on appeal in September 2026, and still sues Pfizer and BioNTech.
current state · 2026-11-06written 2026-11-17
C43inferencemedium confidence
Funding: 2026 cash costs of about $3.8B and about $4B of spending in 2027 against roughly $2.3B to $2.6B of revenue leaves a gap near $1.5B a year; more than $9B of liquidity, including $900M of undrawn loans, covers about five years of that gap, or about three if revenue stalls at 2025's level.
against this

The $3.0B of convertibles count in liquidity but are debt, due in 2032.

current state · 2026-11-12written 2026-11-17
C12management claimmedium confidence
At its 12 November 2026 analyst day Moderna said it will seek US approval of intismeran by year-end and aims for a 2027 launch, with Merck sharing the US launch and leading outside it, about $4B of company spending in 2027 and more than $9B of liquidity at the end of 2026.
against this

A filing is not an approval, and an individualized medicine made for each patient has no precedent at this scale.

forwardwritten 2026-11-17
What we still do not know
  • What the cancer vaccine will cost, and whether Medicare will pay for it on top of Keytruda.
  • Whether fewer cancers coming back turns into longer lives in the melanoma trial.
  • Whether Moderna can make each patient's dose in about six weeks at commercial scale.
The evidence under this - 3 claims
C12management claimmedium confidence
At its 12 November 2026 analyst day Moderna said it will seek US approval of intismeran by year-end and aims for a 2027 launch, with Merck sharing the US launch and leading outside it, about $4B of company spending in 2027 and more than $9B of liquidity at the end of 2026.
against this

A filing is not an approval, and an individualized medicine made for each patient has no precedent at this scale.

forwardwritten 2026-11-17
C10facthigh confidence
In the Phase 3 INTerpath-001 trial, 1,137 patients with high-risk melanoma removed by surgery got intismeran with Keytruda or Keytruda alone; after a median follow-up of 24.6 months recurrence or death fell 42% (hazard ratio 0.58, 95% CI 0.45 to 0.75), 82.2% against 70.0% were free of recurrence at two years, and survival data are immature.
against this

Overall survival is not yet shown, and the trial compares against Keytruda alone, not against other add-on treatments.

historical · INTerpath-001 interim analysis, 2026written 2026-11-17
C13management claimmedium confidence
Management says the adjuvant lung cancer Phase 3 (INTerpath-002) is fully enrolled, as are the kidney and bladder cancer trials, and the kidney cancer Phase 2 reads out around the turn of 2027.
against this

Enrolment says nothing about results; the closest rival's personalised vaccine failed in another tumour (C14).

current state · 2026-11-06written 2026-11-17

What would change our view

  1. Unattractive→NeutralThe price falls back within 20% of fair value

    It needs:

    • ○The share price falls back within 20% of what we think the business is worth.about ≈$38.30 today, 82% below the last close
  2. Unattractive→AttractiveThe price falls 20% under fair value

    It needs:

    • ○The share price falls to 80% of what we think the business is worth.about ≈$21.96 today, 90% below the last close
  3. Unattractive→NeutralIntismeran proves itself beyond melanoma

    It needs all of:

    • ○The lung cancer trial reports a clear cut in cancers coming back at its first look.watched as it happens
    • ○The US approves the vaccine for melanoma at a price near a year of Keytruda.watched as it happens
We would also be wrong if
  • COVID, RSV and flu vaccine sales grow again in 2027, with more than a fifth of US adults taking a COVID shot.

What is coming

  • 12 February 2027 Q4 2026 results and the intismeran filing: Whether the FDA filing went in, whether 2026 revenue landed in the guide and what 2027 spending looks like.
Every dated event ahead
  • 12 February 2027 Q4 2026 results and the intismeran filing: Whether the FDA filing went in, whether 2026 revenue landed in the guide and what 2027 spending looks like.
  • 31 March 2027 Kidney cancer Phase 2 readout for intismeran: The first test of the vaccine outside melanoma.
  • 31 December 2027 FDA decision on intismeran in melanoma: Whether it can be sold, at what price, and how fast each dose can be made.
Since we wrote this
Written
17 Nov
Price the thesis read
$215.27
16 Nov
  • 17 NovThesis writtenUnattractive, high convictionThe cancer vaccine works in melanoma, but half the profit is Merck's and the price sits far above even our bull case.

Sources 23

Where this came from

Sources - 23

Every claim above cites one of these, or states the reasoning that derived it. The quote is frozen at the date it was read: a link can rot, and an agent fetch returns a reading of a page rather than the page. Backs counts the whole claim ledger, so it can name a claim this page does not surface.

  1. S01primarycompany filing2026-02-20
    products, the Merck collaboration, competition, government partnerships, data exclusivity, employees, risk factors and the statements
    backsC01C02C03C05C11C22C32C33C34C37C38C39
  2. S02primarycompany filing2026-11-06
    Q3 revenue by product and region, profit, the 2026 outlook, approvals and pipeline updates
    backsC01C04C06C10C36C43C46
  3. S03primarycompany filing2026-11-06
    the balance sheet, the convertible notes, the Arbutus, GSK and Pfizer litigation, the Recordati licence and the nine-month cash flow
    backsC04C05C07C08C22C30C31C34C36C44
  4. S04primarytranscript2026-11-06
    Third quarter 2026 earnings call transcript (FMP), held 2026-11-06
    data/cache/transcripts/MRNA-2026Q3.json
    management on the oncology trials, the respiratory season, costs and the intismeran launch
    In non small cell lung cancer, the adjuvant Phase 3 study is fully enrolled.
    backsC13
  5. S05primarycompany filing2026-03-16
    share ownership of officers, directors and large holders, and how executives are paid
    backsC27C28
  6. S06primarycompany filing2026-09-01
    the notes' size, coupon, maturity, conversion price and capped call
    backsC08
  7. S07primarycompany filing2026-11-16
    the lower interest margin, the later maturity and the delayed-draw loans
    backsC09C43
  8. S08primarycompany filing2026-09-30
    the new chief operating officer, the retirement of the head of technical operations and five approved vaccines
    backsC01
  9. S09primarycompany filing2026-11-13
    the legal chief's retirement on 31 March 2027
    read, but no claim rests on it
  10. S10secondarynews2026-10-26
    the Phase 3 melanoma results as presented: patients, hazard ratio, two-year rates and immature survival data
    At 2 years, 82.2% of patients receiving the combination were alive without recurrence
    backsC10
  11. S11primarygovernment data2026-04-01
    US melanoma cases and deaths expected in 2026, and the share diagnosed at each stage
    there will be 112,000 new cases of melanoma of the skin and an estimated 8,510 people will die of this disease
    backsC15C42
  12. S12primarycompany release2026-09-01
    the list price of the medicine intismeran is given with, current as of September 2026
    The list price for each indicated dose of KEYTRUDA when given every 3 weeks is $12,517.44.
    backsC16C41C42
  13. S13secondarynews2026-08-31
    that the closest rival individualized cancer vaccine stopped its colorectal trial on a survival imbalance
    BioNTech announced it has terminated the Phase 2 BNT122-01 trial
    backsC14
  14. S14secondarynews2026-11-12
    the analyst day: filing and launch timing, Merck's role, 2027 spending, liquidity, the VA study and flu vaccine reach
    Moderna expects approximately $4 billion in companywide investment in 2027
    backsC12C35C43
  15. S15primarygovernment data2026-02-22
    CDC COVIDVaxView: adult vaccination coverage, 2025-26 season US Centers for Disease Control and Prevention
    the share of US adults who took a COVID-19 vaccine in the 2025-26 season: 17.5% as of 22 February 2026
    of adults reported having received the 2025─26 COVID-19 vaccine.
    backsC17
  16. S16primarycompany filing2026-11-05
    Comirnaty and Abrysvo revenue in the quarter and nine months against a year earlier
    backsC18
  17. S17primarycompany filing2026-03-10
    BioNTech's COVID-19 vaccine revenue against its total, and its own individualized cancer vaccine programme
    backsC19
  18. S18primarycompany filing2026-02-26
    that its protein-based COVID-19 vaccine is now sold through Sanofi
    backsC20
  19. S19secondaryvendor data2026-11-17
    Research pack frozen beside this thesis, 2026-11-17
    content/MRNA/research-pack.json
    the 16 November close, returns and their decomposition, the cohort, the rating split and its history, target drift, short interest and insider trades
    backsC03C21C22C23C24C25C29C32C44C45
  20. S20secondaryvendor data2026-11-17
    the analysts' average revenue, earnings and operating profit for 2026 to 2030, and how many analysts are behind each year
    backsC26C44C45
  21. S21primarycompany filing2026-11-09
    each open-market sale, its price and whether it was made under a Rule 10b5-1 plan
    backsC29
  22. S22secondaryvendor data2026-11-17
    the closes either side of the melanoma readout, the early leak of the full data and the analyst day
    backsC40
  23. S23primarycompany filing2026-01-12
    2025 revenue of about $1.9B, about $2B of yearly cost cuts, and the first 2026 guide of up to 10% growth
    backsC46
Rendered from content/MRNA/thesis.json · thesis reviewed 2026-11-17. This page explains a company; it does not say what to pay, when to buy or how much.